|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
PBMs: Merck-Medco in the Hot Seat
Author(s)Andra Brichacek
Franklin Lakes, New Jersey-Merck’s pharmacy benefit arm, Merck-Medco, is under fire for switching patients to more expensive pharmaceuticals.
Advertisement
Articles in this issue
about 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
A Five-Year Forecast: Clear Seas Ahead?about 24 years ago
Weak Bones, Strong Marketabout 24 years ago
Approvals: Novartis’ Silver Liningabout 24 years ago
Pfizer and others Pitch Inabout 24 years ago
Oncology: EMEA Approval Lagsabout 24 years ago
Illegal Sales in Indiaabout 24 years ago
Health Plan Premiums: Pharma Takes the Blameabout 24 years ago
Little Elan Becomes a Big DealNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
